Kyle Mikson
Stock Analyst at Canaccord Genuity
(0.88)
# 1,599
Out of 4,623 analysts
56
Total ratings
30%
Success rate
-26.79%
Average return
Main Sectors:
Stocks Rated by Kyle Mikson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Buy | $32 → $20 | $16.26 | +23.00% | 6 | Oct 10, 2024 | |
| EXAS Exact Sciences | Maintains: Buy | $75 | $70.96 | +5.69% | 7 | Sep 13, 2024 | |
| NTRA Natera | Maintains: Buy | $130 → $145 | $130.06 | +11.49% | 3 | Aug 27, 2024 | |
| LUCD Lucid Diagnostics | Maintains: Buy | $3 | $0.78 | +282.95% | 3 | Aug 13, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $3.5 → $3 | $1.98 | +51.52% | 7 | Aug 8, 2024 | |
| TTOO T2 Biosystems | Maintains: Hold | $3 → $5 | $1.48 | +237.84% | 3 | Jul 30, 2024 | |
| GH Guardant Health | Maintains: Buy | $30 → $38 | $21.40 | +77.57% | 4 | Jun 4, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $10 → $6 | $3.00 | +100.00% | 2 | May 14, 2024 | |
| QTRX Quanterix | Maintains: Buy | $32 → $25 | $11.76 | +112.59% | 4 | Apr 29, 2024 | |
| BDSX Biodesix | Reiterates: Buy | $3.5 | $1.69 | +107.10% | 2 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $210 → $120 | $145.54 | -17.55% | 5 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $3.5 → $2 | $0.82 | +142.54% | 2 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $2 | $0.69 | +188.81% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $40 | $31.31 | +27.75% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $2.65 | +164.15% | 1 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $49 | $1.16 | +4,141.38% | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $1.46 | +1,201.37% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.76 | +19,556.66% | 1 | Jan 29, 2021 |
10x Genomics
Oct 10, 2024
Maintains: Buy
Price Target: $32 → $20
Current: $16.26
Upside: +23.00%
Exact Sciences
Sep 13, 2024
Maintains: Buy
Price Target: $75
Current: $70.96
Upside: +5.69%
Natera
Aug 27, 2024
Maintains: Buy
Price Target: $130 → $145
Current: $130.06
Upside: +11.49%
Lucid Diagnostics
Aug 13, 2024
Maintains: Buy
Price Target: $3
Current: $0.78
Upside: +282.95%
Pacific Biosciences of California
Aug 8, 2024
Maintains: Buy
Price Target: $3.5 → $3
Current: $1.98
Upside: +51.52%
T2 Biosystems
Jul 30, 2024
Maintains: Hold
Price Target: $3 → $5
Current: $1.48
Upside: +237.84%
Guardant Health
Jun 4, 2024
Maintains: Buy
Price Target: $30 → $38
Current: $21.40
Upside: +77.57%
Akoya Biosciences
May 14, 2024
Maintains: Buy
Price Target: $10 → $6
Current: $3.00
Upside: +100.00%
Quanterix
Apr 29, 2024
Maintains: Buy
Price Target: $32 → $25
Current: $11.76
Upside: +112.59%
Biodesix
Mar 4, 2024
Reiterates: Buy
Price Target: $3.5
Current: $1.69
Upside: +107.10%
Nov 10, 2023
Downgrades: Hold
Price Target: $210 → $120
Current: $145.54
Upside: -17.55%
Sep 25, 2023
Downgrades: Hold
Price Target: $3.5 → $2
Current: $0.82
Upside: +142.54%
Aug 16, 2023
Maintains: Overweight
Price Target: $3 → $2
Current: $0.69
Upside: +188.81%
Jun 6, 2023
Maintains: Buy
Price Target: $60 → $40
Current: $31.31
Upside: +27.75%
Nov 15, 2022
Maintains: Buy
Price Target: $8 → $7
Current: $2.65
Upside: +164.15%
Mar 30, 2021
Initiates: Overweight
Price Target: $49
Current: $1.16
Upside: +4,141.38%
Jan 29, 2021
Initiates: Overweight
Price Target: $19
Current: $1.46
Upside: +1,201.37%
Jan 29, 2021
Initiates: Overweight
Price Target: $150
Current: $0.76
Upside: +19,556.66%